- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Lupin Limited has received U.S. FDA approval for its Abbreviated New Drug Application (ANDA) for Ipratropium Bromide Nasal Solution (Nasal Spray), 0.03%, a generic equivalent of Boehringer Ingelheim's Atrovent® Nasal Spray. This product, manufactured at Lupin's Pithampur facility, targets symptomatic relief for rhinorrhea associated with allergic and nonallergic perennial rhinitis. The estimated annual sales for the original Atrovent® in the U.S. are approximately USD 22 million. This development enhances Lupin's portfolio in the respiratory segment, which could positively affect its market presence and revenue growth moving forward. Investors should monitor this growth opportunity closely.